Mercator MedSystems announced last week that it finished enrollment for a six-month trial of its Bullfrog micro-infusion device in patients with below-the-knee critical limb ischemia.
The Emeryville, Calif.-based company’s 120-patient trial was designed to evaluate if Mercator’s Bullfrog device can improve blood flow and reduce the occurrence of restenosis following atherectomy-based revascularization.
Mercator’s micro-infusion device delivers drugs directly through blood vessel walls and into adventital tissues. The Bullfrog device is tipped with a microneedle that is protected by a balloon as it is guided through the vasculature. When the device reaches its intended injection site, the balloon inflates and slides the microneedle through the vessel wall.
“This technology is so hyper-efficient,” CEO Trent Reutiman told Drug Delivery Business News. “It delivers the drug very locally and precisely to the tissue surrounding a blood vessel or an airway.”